CIK cells have been also used as a promising platform for genetic modification with CAR molecules targeting CD123+/CD33+ acute myeloid leukemia (AML) (115), CD19+ acute lymphoblastic leukemia (ALL) (116), ErbB2+ rhabdomyosarcoma (RMS) (117), CSPG4+ (118) and CD44v6+ (119) soft-tissue sarcomas (STS), showing an increased cytotoxicity compared to untransduced CIK cells. This evidence concerns the gene CD33 and acute myeloid leukemia.